- Not Fee assured
- Awaiting verification
- Video and telephone consultations
Dr Timothy Harrower gained his medical degree at the University of Cape Town. After gaining membership at the Royal College of Physicians he was awarded a Wellcome Trust Clinical Research Grant. This allowed him to undertake research into neural stem cell biology and the mechanisms of neural transplant rejection at the Cambridge Centre for Brain Repair (University of Cambridge) where he read for a Ph.D in neuroscience. In addition he was involved in managing all the patients with Huntington's Disease who had received neural transplants. Neurology specialist training was completed in Cambridge during which time extensive experience in the use of Botulinum Toxin usage was gained.
In 2006 he was appointed Consultant Neurologist at the Royal Devon and Exeter NHS Foundation Trust and as a visiting neurologist at North Devon District Hospital. He also runs the Mardon Neuro-rehabilitation Centre (sited adjacent to Nuffield Health Exeter Hospital).
He is currently the principle investigator in research projects including investigations in optimising botulinum toxin injections in cervical dystonia. Including generating economic models of Botulinum Toxin usage in dystonia, and initiating local involvement in an International Collaboration which aims to undertake genetic analysis of patients with Dystonia. He is currently on of the Directors of the British Neurotoxin Network (BNN).
Areas of interest
• Parkinsons disease • Multiple sclerosis • Headache / migraine • Movement disorders
Current NHS consultant posts held
Consultant Neurologist Royal Devon and Exeter NHS Trust
Consultant Neurologist North Devon District Hospital Barnstaple
Honorary Senior Clinical Lecturer -Exeter University
Consultant in Charge of Mardon Neuro-Rehabilitation Centre
Sport - Tennis, Long Boarding, Running
Gardening and the pursuit of an excellent lawn
4 Clinical Excellence Awards
(Additional) Languages spoken
Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NEST-UK safety report ISRCTN no 36485475.
Journal of Neurology, Neurosurgery and Psychiatry Vol 73, Number 6, December 2002, 678-686
Is there a future for neural transplantation?
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders.
Drugs Today (Barc) 2004 Feb;40(2):171-89
Voltage gated potassium channel antibody related Limbic Encephalitis: Extending the clinical phenotype
Nature Clinical Practice Neurology. 2006 Jun;2(6):339-43.
Lewy Bodies in Parkinson’s disease: protector or perpetrator?
Experimental Neurology 2005 Sep;195(1):1-6
Cell therapies for neurological disease – From bench to clinic to bench.
Expert Opinion in Biological Therapy 2005 Mar;5(3):289-91
LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation
European Journal of Human Genetics (2005), 1–5
Psychiatric Presentation of Voltage-Gated Potassium Channel Antibody Associated Encephalopathy: Case Report
British Journal of Psychiatry 2006 Aug;189:182-3.
POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease.
Arch Neurol. 2008 Jan;65(1):133-6.
TB or not TB?
Am J Med. 2008 Aug;121(8):684-6.
Stent placement for management of a small parasagittal meningioma.
J Neurosurg. 2008 Feb;108(2):377-81.
Management of sialorrhoea in motor neuron disease: A survey of current UK practice.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 May 7
Molybdenum cofactor deficiency presenting with a parkinsonism-dystonia syndrome.
Mov Disord. 2013 Mar;28(3):399-401
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):657-65.
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
International Multiple Sclerosis Genetics Consortium (IMSGC),
Nat Genet. 2013 Nov;45(11):1353-60.
Reference number 4074904
- Nuffield Health Exeter Hospital
- 18:00 - 20:00
- 01392 262123
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.